Fundraising FoxProspect Venture Partners — Full Portfolio
34 tracked investments · listed companies and verified rows first
Insmed is a biopharmaceutical company that provides grants and charitable funding to support healthcare provider education and patient care initiatives focused on nontuberculous mycobacterial lung disease, non-cystic fibrosis bronchiectasis, and other serious lung diseases.
BiotechDigital HealthHealthtechMedical Devices
Will Lewis(Chair and Chief Executive Officer)inGeoffrey AllaninSara Bonstein(Chief Financial Officer)inRoger Adsett(Chief Operating Officer)Martina Flammer(Chief Medical Officer)inS. Nicole Schaeffer(Chief People Strategy Officer)in
Co-investorsBessemer Venture PartnersF-Prime CapitalForesite CapitalHercules Capital, Inc.OrbiMedRidgeback Capital+1 more
Curileum develops regenerative medicine therapies targeting intestinal stem cells to prevent colorectal cancer.
BiotechHealthtechMedical DevicesLondon, GB
Dr Jeff Moore(Founder & CEO)
Co-investorsAtlas VentureBiotechnology Value FundCanaan PartnersOxford Technology Management
20n uses machine learning and computational biology to predict DNA sequences for industrial biotech and pharmaceutical applications.
AI & Machine LearningBiotechHealthtechSan Francisco, US
Saurabh Srivastava(CEO)inChris Anderson(CSO)
Co-investorsY CombinatorBlumberg CapitalGreat Oaks Venture CapitalKhosla VenturesLin, Bill | A10 VenturesPoint Reyes Management+2 more
Amicus is a rare disease biotechnology company developing medicines for people with genetically defined conditions.
BiotechHealthtechCranbury, US
Daphne Quimi(Executive Officer)John Crowley(Founder)William D. Baird, III(Executive Officer)
BoardCraig A. Wheeler(Director)Ted W. Love(Director)inMargaret G. McGlynn(Director)
Co-investorsAvoro Capital AdvisorsCanaan PartnersFrazier Life SciencesNew Enterprise Associates (NEA)
Bristol Myers Squibb is a biopharmaceutical company that develops and delivers medicines across oncology, hematology, neuroscience, immunology, and cardiovascular disease areas.
BiotechHealthtechMedical DevicesNew York, US
Co-investorsKleiner PerkinsNew Enterprise Associates (NEA)Nextech InvestRho Capital PartnersRho VenturesRiverVest Venture Partners+2 more
GrubMarket is a food tech company operating a B2B and B2C marketplace in the U.S. and Canada, offering both wholesale produce delivery at discounted prices and AI-powered SaaS software solutions for food supply chain businesses including inventory management, warehouse operations, and eCommerce platforms.
B2B MarketplacesE-commerceEnterprise SoftwareFoodTechLogistics & Supply ChainSaaSSan Francisco, US
Mike Xu(CEO, , President)inYang WeiBrian Gallagher(Chief Of Staff)inJack Tao(CTO)Genevieve Wang(Product)Bryan Barsness(Vice President of Software Sales \u0026 Marketing)
Co-investorsAlumni VenturesBascom VenturesBattery VenturesBuilders + BackersCastor VenturesCeltic House Asia Partners+50 more
Jazz Pharmaceuticals is a biopharmaceutical company developing treatments for rare diseases and cancers, with a focus on oncology and biomarker-driven therapies such as those targeting HER2-expressing cancers.
BiotechHealthtech
Co-investorsLongitude CapitalRex Health VenturesSolas BioVentures
Aesthetic-medicine biopharma behind KYBELLA (deoxycholic acid) injection, acquired by Allergan in 2015 for ~$2.1 billion.
Allen Chao(Founder)
Co-investorsAisling CapitalARCH Venture PartnersMESA VERDE VENTURE PARTNERSSchooner CapitalALTITUDE LIFE SCIENCE VENTURESFoley Ventures+2 more
Lully develops an under-mattress device that uses timed vibrations to prevent night terrors in children.
HealthtechWellness & FitnessSan Francisco, US
Varun Boriah(CEO)inAndy Rink(CMO)in
Co-investorsStartXY Combinator8capitaAgrolimen VenturesAstiaGFO Companies+3 more
Nanosys develops Quantum Dot technology and materials, providing samples, R&D collaboration, and scaled production for partners building display and other advanced-material products.
Advanced ManufacturingDeep TechHardwareNew MaterialsSemiconductorsMilpitas, US
Jason Hartlove(Executive Officer, Director)inJian Chen(Executive Officer)inRussell Kempt(Executive Officer)inNoland Granberry(Executive Officer)inDr. Martin Devenney(Co Chief Executive Officer and Assistant Secretary)Dr. Hirokazu Sasaki(President & CEO and Treasurer, Shoei Electronic Materials, Inc. • Operating Officer & Division Manager QD Business Dept., Shoei Chemical, Inc.)
Co-investorsArcher Capital GroupArcher Venture CapitalStructural CapitalTEL Venture Capital, Inc.VenrockARCH Venture Partners+4 more
HealthtechBedford, US
Christopher von Jako(Executive Officer, Director)inJudith M. Huber(Executive Officer)inCharles Carignan(Executive Officer, Director)Eric Swanson(Director)
BoardRussell Hirsch(Director)Mark Levin(Director)in
Co-investorsThird Rock Ventures
Opus Medical provides personalized case management services for injured workers, matching clinical oversight to the severity of each injury.
Digital HealthEnterprise SoftwareHealthtechInsurTechMedical DevicesNashville, US
Melissa D. Tonn(Chief Medical Officer)in
Co-investorsCouncil
Portola develops research and investigates new targets, modalities, and technologies to address rare disease challenges for patients and their families.
BiotechDigital HealthHealthtechMedical Devices
PartnerRussell Hirsch· led
Co-investorsBluebird VenturesFrazier Life SciencesLightstone VenturesKhosla VenturesNFDG
Firmenich is a co-creation and innovation partner specializing in nutrition, health, and beauty ingredients and solutions.
ConsumerHealthtechNew MaterialsGeneva, CH
Co-investorsBay City CapitalRho Ventures
SentreHeart appears to now redirect to AtriCure, Inc., a medical device company.
BiotechHardwareHealthtechMedical DevicesRedwood City, US
Russell Seiber(Executive Officer, Director)inPam Simons(Executive Officer)inGreg Fung(Executive Officer)Robert Strasser(Executive Officer)in
BoardPhil Young(Director)inVictor Tong(Director)
PartnerRussell Hirsch· led
Co-investorsDecheng CapitalUS Venture PartnersDeerfield Management CompanyU.S. Venture PartnersVivo Capital
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Amira PharmaceuticalsAveo PharmaceuticalsAzelon PharmaceuticalsCabochonComplete GenomicsHansen MedicalHealth Systems TechnologiesIdun PharmaceuticalsInfinity PharmaceuticalsMillennium PharmaceuticalsNgm BiopharmaceuticalsNovaceptRinat NeuroscienceSatori PharmaceuticalsSurgRxTercicaTherOxTopica PharmaceuticalsTrubion
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.